Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Pantaleo, Maria A ^a,b   Mandrioli, Anna ^a   Saponara, Maristella ^a   Nannini, Margherita ^a   Erente, Giovanna ^c   Lolli, Cristian ^a   Biasco, Guido ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Ospedale S Bassiano   (Italy)

Author keywords

Cardiac ischemia infarction; Cardiotoxicity; Coronary syndrome; Renal cell carcinoma; Sorafenib

Indexed keywords

SORAFENIB;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR RISK; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ATRIUM THROMBOSIS; HEART FUNCTION; HEART INJURY; HEART MUSCLE ISCHEMIA; HUMAN; INFERIOR CAVA VEIN THROMBOSIS; KIDNEY METASTASIS; LIVER RESECTION; MALE; NEPHRECTOMY; PATIENT MONITORING; THORAX PAIN; THROMBECTOMY; TUMOR THROMBUS; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84861963722     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-231     Document Type: Article

References (23)

1. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology, Kidney Cancer, http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. V. 2.2010, National Comprehensive Cancer Network.
2. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011, 16(2):45-50. 10.1634/theoncologist.2011-S2-45, 21346039.
3. Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011, 9(1):1-29.
4. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH. Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116(5):1272-1280. 10.1002/cncr.24864, 20082451.
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R. Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134. 10.1056/NEJMoa060655, 17215530.
6. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010, 49(3):287-297. 10.3109/02841860903524396, 20156114.
7. Richards CJ, Je Y, Schutz FAB, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK. Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib. J Clin Oncol 2011, 29:3450-3456. 10.1200/JCO.2010.34.4309, 21810682.
8. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28(13):2280-2285. 10.1200/JCO.2009.27.2757, 20351323.
9. Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011, 36(4):348-351. 10.1007/s00059-011-3444-5, 21584715.
10. Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, Shono M, Ogawa H. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009, 54(3):512-515. 10.1016/j.jjcc.2009.03.009, 19944333.
11. Porto I, Leo A, Miele L, Pompili M, Landolfi R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010, 7(8):476-480. 10.1038/nrclinonc.2010.67, 20479781.
12. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20):3312-3318. 10.1200/JCO.2008.19.5511, 19451442.
14. Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011, 23:23.
15. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019. 10.1016/S0140-6736(07)61865-0, 2643085, 18083403.
16. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19(9):1613-1618. 10.1093/annonc/mdn168, 18436521.
17. Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009, 20(9):1535-1542. 10.1093/annonc/mdp025, 19474115.
18. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26(32):5204-5212. 10.1200/JCO.2007.15.6331, 18838713.
19. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and traslantion of preclinical models to clinical outcomes. Nat Rev Cancer 2011, 10:111-126.
20. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7(5):332-344. 10.1038/nrc2106, 17457301.
21. Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, Hikoso S, Hirotani S, Asahi M, Taniike M, Nakai A, Tsujimoto I, Matsumura Y, Miyazaki J, Chien KR, Matsuzawa A, Sadamitsu C, Ichijo H, Baccarini M, Hori M, Otsu K. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004, 114(7):937-943. 518660, 15467832.
22. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96(12):1788-1795. 10.1038/sj.bjc.6603813, 2359962, 17519900.
23. Lim TJ, Lee JH, Chang SG, Lee CH, Min GE, Yoo KH, Jeon SH. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate. Urol Int 2010, 85(4):475-478. 10.1159/000321175, 20975258.